Paper Key : IRJ************783
Author: Rushikesh G Kasar,Nikita D Kale ,Nikita S Kapkar ,Sakshi R Khatal,Ankit P Dere ,Pavan A Kadlag
Date Published: 06 Apr 2025
Abstract
The global rise in antibiotic-resistant bacteria has created an urgent need for novel antimicrobial agents. Teixobactin, a recently discovered antibiotic, has emerged as a promising solution due to its unique mechanism of action and resistance-resistant properties. Derived from Eleftheria terrae through iChip technology, teixobactin effectively targets Gram-positive bacteria by binding to highly conserved precursors of cell wall biosynthesis, such as Lipid II and Lipid III. Unlike conventional antibiotics, it does not act on bacterial proteins, making the development of resistance highly unlikely. This review explores the discovery, structure, mechanism of action, antimicrobial spectrum, pharmacokinetics, resistance profile, and future prospects of teixobactin. Challenges in its clinical translation, including issues related to synthesis, formulation, and spectrum expansion, are also discussed
DOI Requested